Insulin-like growth factor-binding proteins play a significant role in the molecular response to imatinib in chronic...

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Imatinib (IM) is a primary treatment for chronic myeloid leukemia (CML).
• Drug resistance, often linked to insufficient apoptosis and uncontrolled cell proliferation, limits IM efficacy in some CML patients.
• Identifying novel biomarkers for IM resistance is crucial for improving treatment outcomes.

Purpose of the Study:

• To investigate the differential expression profile of apoptosis-related proteins in IM-sensitive (K562) and IM-resistant (K562/G) CML cells.
• To identify potential novel biomarkers associated with imatinib resistance in CML.

Main Methods:

• Human apoptosis antibody array screening of 46 proteins in K562 and K562/G cell lines.
• Differential protein expression analysis to identify candidate biomarkers.
• Validation of selected insulin-like growth factor-binding proteins (IGFBPs) using reverse transcription-quantitative PCR and western blotting.
• Correlation analysis of IGFBP expression with BCR-ABL fusion protein levels.

Main Results:

• Twenty apoptosis-related proteins showed differential expression between K562 and K562/G cells.
• Key differentially expressed proteins included secreted caspase-8, IGFBP-1, IGFBP-2, IGFBP-3, caspase-3, and p27.
• IGFBP-1 levels were higher in K562/G cells, while IGFBP-2 and IGFBP-3 levels were significantly decreased compared to K562 cells.
• Decreasing IGFBP-3 levels correlated with increasing BCR-ABL levels, suggesting a link to IM resistance.

Conclusions:

• Insulin-like growth factor-binding proteins (IGFBP)-1, IGFBP-2, and IGFBP-3 are differentially expressed in IM-resistant CML cells.
• These IGFBPs represent potential novel biomarkers for predicting or monitoring imatinib resistance in chronic myeloid leukemia.
• Further investigation is warranted to elucidate the precise role of these IGFBPs in CML drug resistance mechanisms.